BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Popovics P, Schally AV, Block NL, Rick FG. Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists. World J Clin Urol 2014; 3(3): 184-194 [DOI: 10.5410/wjcu.v3.i3.184]
URL: https://www.wjgnet.com/2219-2816/full/v3/i3/184.htm
Number Citing Articles
1
Rosemeire M. Kanashiro-Takeuchi, Luca Szalontay, Andrew V. Schally, Lauro M. Takeuchi, Petra Popovics, Miklos Jaszberenyi, Irving Vidaurre, Marta Zarandi, Ren-Zhi Cai, Norman L. Block, Joshua M. Hare, Ferenc G. Rick. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptorOncotarget 2015; 6(12): 9728 doi: 10.18632/oncotarget.3303
2
Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves. Early investigational agents for the treatment of benign prostatic hyperplasia’Expert Opinion on Investigational Drugs 2024; 33(4): 359 doi: 10.1080/13543784.2024.2326023
3
Petra Popovics, Andrew V. Schally, Luis Salgueiro, Krisztina Kovacs, Ferenc G. Rick. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cellsProceedings of the National Academy of Sciences 2017; 114(6): 1359 doi: 10.1073/pnas.1620884114